About Marius Pharmaceuticals
Marius Pharmaceuticals is a company based in Raleigh (United States) founded in 2017 by Himanshu H Shah and Om Dhingra. It operates as a Direct-to-Consumer (D2C). Marius Pharmaceuticals has raised $11.61 million across 2 funding rounds. Marius Pharmaceuticals offers products and services including KYZATREX. Marius Pharmaceuticals operates in a competitive market with competitors including Auxilium Pharmaceuticals, Xanodyne Pharmaceuticals, Microchips Biotech, Agile Therapeutics and Asarina Pharma, among others.
- Headquarter Raleigh, United States
- Founders Himanshu H Shah, Om Dhingra
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Marius Pharmaceuticals
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$11.61 M (USD)
in 2 rounds
-
Latest Funding Round
$6.01 M (USD), Series B
Oct 05, 2021
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Marius Pharmaceuticals
Marius Pharmaceuticals offers a comprehensive portfolio of products and services, including KYZATREX. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Oral testosterone therapy for men with deficiency issues.
Unlock access to complete
Unlock access to complete
Funding Insights of Marius Pharmaceuticals
Marius Pharmaceuticals has successfully raised a total of $11.61M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $6.01 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $6.0M
-
First Round
First Round
(16 May 2019)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2021 | Amount | Series B - Marius Pharmaceuticals | Valuation |
investors |
|
| May, 2019 | Amount | Series B - Marius Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Marius Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Marius Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Marius Pharmaceuticals Comparisons
Competitors of Marius Pharmaceuticals
Marius Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Auxilium Pharmaceuticals, Xanodyne Pharmaceuticals, Microchips Biotech, Agile Therapeutics and Asarina Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutics and drug-device combinations for urology and sexual health
|
|
| domain | founded_year | HQ Location |
Developer of drugs for women's health and pain management
|
|
| domain | founded_year | HQ Location |
Microchip implants for wireless drug delivery are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for women's healthcare are developed and offered.
|
|
| domain | founded_year | HQ Location |
Pharmaceuticals for PMDD, migraine, and Tourette syndrome are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Marius Pharmaceuticals
Frequently Asked Questions about Marius Pharmaceuticals
When was Marius Pharmaceuticals founded?
Marius Pharmaceuticals was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is Marius Pharmaceuticals located?
Marius Pharmaceuticals is headquartered in Raleigh, United States. It is registered at Raleigh, North Carolina, United States.
Who is the current CEO of Marius Pharmaceuticals?
Shalin Y Shah is the current CEO of Marius Pharmaceuticals.
Is Marius Pharmaceuticals a funded company?
Marius Pharmaceuticals is a funded company, having raised a total of $11.61M across 2 funding rounds to date. The company's 1st funding round was a Series B of $5.6M, raised on May 16, 2019.
What does Marius Pharmaceuticals do?
Marius Pharmaceuticals is dedicated to revolutionizing hormone health through science-backed therapies. The company addresses testosterone deficiency, impacting metabolic vitality and well-being for both men and women. Solutions are developed to improve conditions like obesity, type 2 diabetes, and menopausal symptoms in women. Research initiatives are supported to explore hormone imbalances across various comorbidities and patient populations. Innovative oral testosterone therapy, such as KYZATREX, is provided to treat adult men with low testosterone levels due to specific medical conditions.
Who are the top competitors of Marius Pharmaceuticals?
Marius Pharmaceuticals's top competitors include Agile Therapeutics, Auxilium Pharmaceuticals and Peptonic Medical.
What products or services does Marius Pharmaceuticals offer?
Marius Pharmaceuticals offers KYZATREX.